Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fagan

Showing results (301-310 of 489) with videos related to

Pageof 49
Sort By:
Brain Sciences|August 26, 2022
Changes in Oral Microbial Diversity in a Piglet Model of Traumatic Brain InjuryJulie Heejin Jeon, Jeferson M Lourenco, Madison M Fagan, et al.
Diabetes Care|March 6, 2014
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trialBruce A Perkins, David Z I Cherney, Helen Partridge, et al.
Neurobiology of Aging|December 12, 2018
Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer NetworkAurélie Bussy, B Joy Snider, Dean Coble, et al.
Circulation|December 17, 2013
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitusDavid Z I Cherney, Bruce A Perkins, Nima Soleymanlou, et al.
Pain Medicine (Malden, Mass.)|February 27, 2015
Evaluation of a telementoring intervention for pain management in the Veterans Health AdministrationJoseph W Frank, Evan P Carey, Katherine M Fagan, et al.
Journal of Clinical and Experimental Neuropsychology|January 17, 2022
Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testingHannah Wilks, Andrew J Aschenbrenner, Brian A Gordon, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 21, 2018
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Chengjie Xiong, Eric M McDade, et al.
Biological Psychiatry|February 20, 2014
Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluidOscar Harari, Carlos Cruchaga, John S K Kauwe, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2021
Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tauOmar H Butt, Karin L Meeker, Julie K Wisch, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2008
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta depositionJohn S K Kauwe, Carlos Cruchaga, Kevin Mayo, et al.
Pageof 49

Showing results (301-310 of 489) with videos related to

Sort By:
Pageof 49
Brain Sciences|August 26, 2022
Changes in Oral Microbial Diversity in a Piglet Model of Traumatic Brain InjuryJulie Heejin Jeon, Jeferson M Lourenco, Madison M Fagan, et al.
Diabetes Care|March 6, 2014
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trialBruce A Perkins, David Z I Cherney, Helen Partridge, et al.
Neurobiology of Aging|December 12, 2018
Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer NetworkAurélie Bussy, B Joy Snider, Dean Coble, et al.
Circulation|December 17, 2013
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitusDavid Z I Cherney, Bruce A Perkins, Nima Soleymanlou, et al.
Pain Medicine (Malden, Mass.)|February 27, 2015
Evaluation of a telementoring intervention for pain management in the Veterans Health AdministrationJoseph W Frank, Evan P Carey, Katherine M Fagan, et al.
Journal of Clinical and Experimental Neuropsychology|January 17, 2022
Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testingHannah Wilks, Andrew J Aschenbrenner, Brian A Gordon, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 21, 2018
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Chengjie Xiong, Eric M McDade, et al.
Biological Psychiatry|February 20, 2014
Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluidOscar Harari, Carlos Cruchaga, John S K Kauwe, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2021
Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tauOmar H Butt, Karin L Meeker, Julie K Wisch, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2008
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta depositionJohn S K Kauwe, Carlos Cruchaga, Kevin Mayo, et al.
Pageof 49